Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial
贝伐珠单抗生物类似药SIBP04与贝伐珠单抗（阿瓦斯汀®）一线治疗局部晚期或转移性非鳞状非小细胞肺癌的疗效和安全性比较：一项随机、双盲、3期临床试验
期刊:Cancer Pathogenesis and Therapy
影响因子:2.8
doi:10.1016/j.cpt.2025.01.001
Shi, Yuankai; Bi, Minghong; Li, Qingshan; Wang, Guolei; Chen, Jianhua; Li, Mingjun; Shi, Jianhua; Mei, Jiazhuan; Ji, Yinghua; Xia, Qingdi; Feng, Yuanqing; Xu, Shufeng; Zhang, Tongmei; Gao, Xiaohui; Tang, Shubin; Weng, Jie; Cao, Zhuo; Wu, Hongbo; Ren, Xiubao; Xie, Hua; Liu, Hua; Liu, Qiang; Yin, Xing; Luo, Xiaoyong; Chen, Jun; Zhang, Haiming; Guo, Zhiyuan; Ding, Cuimin; Jin, Xin; Sun, Rongli; Yang, Sheng
